SELMA CIRRIK, Erdal BENLİ, Sema Nur AYYILDIZ, ERSAGUN KARAGÜZEL, Ayper KAÇAR, TEVFİK NOYAN, Ali AYYILDIZİ, SİBEL KÖKTÜRK

Parsiyel Üreter Obstrüksiyonunda Tadalafilin Etkisi

Amaç: Farklı deneysel modellerde yapılan çalışmalarda, Fosfodiesteraz-5 inhibitörlerinin böbrekler için koruyucu olduğu gösterilmiştir. Bu çalışma-da spesifik bir fosfodiesteraz-5 inhibitörü olan tadalafilin parsiyel üreter obstrüksiyonundaki olası renoprotektif etkisi incelenmiştir. Gereç ve Yöntem: Erkek Sprague-Dawley sıçanlar sham (S), tek taraflı parsiyel obstrüksiyon (P) ve tadalafil tedavisi (10 mg/72 saat, intragastrik) alan obstrüksiyon grubu (PT) olmak üzere, üçe ayrılmıştır (n =6). Obstrüksiyondan 2 hafta sonra, serum ve idrar kreatinin ile üriner sistatin-c ölçümü yapılmış, GFR hesaplanmıştır. Histolojik incelemeyle böbrekteki dejeneratif değişimler değerlendirilmiştir. Sonuçlar, ortalama±standart sapma olarak verilmiştir. İstatistiksel karşılaştırmalarda one-way ANOVA ve Bonferroni testi kullanılmış, p

The Effects of Tadalafil on The Partial Ureteral Obstruction

Objective: Previous studies in different experimental models have shown protective effects of phosphodiesterase-5 inhibitors for kidneys. In the present study, the possible renoprotective effect of tadalafil, a specific phosphodiesterase-5 inhibitor, was examined during partial ureter obstruction. Material and Method: Male Sprague-Dawley rats were divided into 3 groups (n =6) as sham (S), unilateral partial obstruction (P) and tadalafil treated (10 mg/72 hours, intragastric) obstruction (PT). Two weeks after obstruction, creatinine measurements performed in serum and urine, urinary cystatin-c levels were measured and GFR values were calculated. Histological examination was performed to evaluate degenerative changes in the kidney. The results are given as mean±standard deviation. Statistical comparisons were performed by one-way ANOVA and Bonferroni test, with p

PDF

___

Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis 2001; 37: 233–43.
Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417-30.
Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-7.
Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-52.
Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-34.
Uslu A, Tasli FA, Nart A et al. Human kidney histopathology in acute obstructive jaundice: a prospective study. Eur J Gastroenterol Hepatol 2010; 22: 1458-65.
Forbes MS, Thornhill BA, Chevalier RL. Proximal tubular injury and rapid formation of atubular glomeruli in mice with unilateral ureteral obstruction: a new look at an old model. Am J Physiol Renal Physiol 2011; 301: F110-17.
Aversa A: Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes 2010; 1: 3-7.
Cheng J, Grande JP. Cyclic nucleotide phosphodi-esterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med 2007; 232: 38-51.
Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol 2006;187: 433-46.
Sharma SP. Nitric oxide and the kidney. Indian J Nephrol 2004; 14: 77-84.
Sun D, Wang Y, Liu C, Zhou X, Li X, Xiao A. Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction. Life Sci 2012; 90: 900-9.
Hohenstein B, Daniel C, Wagner A, Stasch JP, Hugo C. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix ac-cumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 2005; 288: F685-93.
Cheng J, Grande JP. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med 2007; 232: 38-51.
Fang L, Radovits T, Szabó G, Mózes MM, Rosi-vall L, Kökény G. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal da-mage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. Nephrol Dial Transplant 2013; 28: 1751-61.
Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. Sildenafil, a phosphodiesterase type 5 inhibitor, at-tenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 2011; 162: 1389-400.
Guzeloglu M, Yalcinkaya F, Atmaca S ve ark. The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. Urol Int 2011; 86: 197-203.
Akgül T, Huri E, Yagmurdur H, Ayyıldız A, Ustün H, Germiyanoğlu C. Phosphodiesterase 5 inhibi-tors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study. Kaohsiung J Med Sci 2011; 27: 15-19.
Cui W, Maimaitiyiming H, Qi X, et al. Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Am J Physiol Renal Physiol 2014; 306: F996-1007.
Puvvada S, Mylarappa P, Aggarwal K, Patil A1, Joshi P, Desigowda R. Comparative efficacy of tadalafil versus tamsulosin as the medical expulsive therapy in lower ureteric stone: a prospective randomized trial. Cent European J Urol 2016; 69: 178-82.
Jayant K, Agrawal R, Agrawal S. Tamsulosin versus tamsulosin plus tadalafil as medical expulsive therapy for lower ureteric stones: a randomized controlled trial. Int J Urol 2014; 21: 1012-5.
Gasanov F, Aytac B, Vuruskan H. The effects of tadalafil on renal ischemia reperfusion injury: an experimental study. Bosn J Basic Med Sci 2011; 11: 158-62.
Cırrık S, Benli E, Ayyıldız SN, Karagüzel E, Ka-çar A, Noyan T, Ayyıldız A, Köktürk S. The effect of tadalafil on renal fibrosis induced by ureteral obstruction. West Indian Med J 2017; DOI: 10. 7727/wimj.2016.518
Thiemermann C, Patel NS, Kvale EO, et al. High density lipoprotein (HDL) reduces renal ische-mia/reperfusion injury. J Am Soc Nephrol 2003; 14: 1833-43.
Galarreta CI, Thornhill BA, Forbes MS, Simpkins LN, Kim DK, Chevalier RL. Transforming growth factor-β1 receptor inhibition preserves glomerulotubular integrity during ureteral obstruction in adults but worsens injury in neonatal mice. Am J Physiol Renal Physiol 2013; 304: F481-90.
Yoo KH, Thornhill BA, Forbes MS, Chevalier RL. Compensatory renal growth due to neonatal ureteral obstruction: implications for clinical studies. Pediatr Nephrol 2006; 21: 368-75.
Wu CF, Chiang WC, Lai CF, et al. Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transi-tion in obstructive kidney fibrosis. Am J Pathol 2013;182: 118-31.
Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29–34.
Prozialeck WC, VanDreel A, Ackerman CD, et al. Evaluation of cystatin C as an early biomarker of cadmium nephrotoxicity in the rat. Biometals 2016; 29: 131-46.
Sasaki D, Yamada A, Umeno H, et al. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 2011; 16: 553-66.
Guan Z, Miller SB, Greenwald JE. Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int 1995; 47: 1569-75.
Choi DE, Jeong JY, Lim BJ, et al. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 2009; 297: F362-70.
Bae EH, Kim IJ, Joo SY, et al. Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res 2012; 36: 248-57.
Cadirci E, Halici Z, Odabasoglu F, et al. Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clin Exp Immunol 2011; 166: 374-84.
Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 2005; 68: 2131-42.